NCT00372710View on ClinicalTrials.gov

Safety/Efficacy of Intravenous Zoledronic Acid When Added to Standard Therapies in Patients With Breast Cancer and Metastatic Bone Lesions

PHASE3TerminatedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2002

Conditions
Breast Cancer With Bone Metastasis
Interventions
DRUG

Zoledronic acid

Trial Locations (1)

Unknown

Freiburg im Breisgau

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY